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Tissue polypeptide antigen (TPA) is a protein
produced by rapidly growing tissues, such as
placenta and neoplasms (Bj6rklund et al., 1976;
Bjorklund, 1978). Increased serum levels of this
antigen have been observed in a variety of
malignant diseases of different origin: i.e. lung,
breast, stomach and colorectal cancer (Menendez-
Botet et al., 1978; Schlegel et al., 1981). They have
also been detected in several acute and chronic
inflammatory conditions, especially liver cirrhosis
and acute hepatitis (Bj6rklund, 1980). Only the
occasional report appears in the literature on TPA
measurements in pancreatic cancer (Andriulli et al.,
1983). Moreover few data are available on the
utility of serum TPA assay in the differential
diagnosis between pancreatic cancer and chronic
pancreatitis (Panucci et al., 1984).
The aim of the present investigation was to
evaluate the role of TPA in detecting pancreatic
malignancy and its value in distinguishing
pancreatic cancer from other pancreatic and benign
extra-pancreatic gastrointestinal conditions.
A total of 106 subjects were studied: 29 control
subjects (19 male, 10 female, age range, 37-66
years) who were healthy members of the medical
staff and blood donors; 28 with pancreatic cancer
of duct cell origin (Cubilla & Fitzgerald, 1978) (20
male, 8 female, aged 43-71) always histologically
confirmed; staging was: T,NoMo (3), T2N1Mo (6),
T2N1M, (9), T3AM, (10); 24 with chronic
pancreatitis (22 male, 2 female, aged 26-64) (7 with
calcified chronic pancreatitis) diagnosed on the
basis of the following examinations: abdominal
x-ray for pancreatic calcifications, pancreatic
ultrasonography, endoscopic retrograde pan-
creatography, CAT scanning. The diagnosis of
chronic pancreatitis was always histologically
confirmed on surgical biopsies. Twenty five were
affected by gastrointestinal extra-pancreatic diseases
of a nonmalignant nature (11 male, 14 female, aged
37-81): liver cirrhosis (6 cases), primary biliary
cirrhosis (1), gallstones (4), common duct stones
(3), benign stenosis of the papilla of Vater (2),
chronic gastritis (4), duodenal ulcer (3), irritable
colon (2). Diagnosis was made on the basis of the
clinical picture and on the results of specific
radiological and histological procedures.
Serum TPA determination was performed by an
RIA procedure (Prolifigen RIA kit, AB Sangtec
Medical, Bromma, Sweden). The intra-assay
(no = 15, mean= 125.5, s.d. =6.2UI-) and inter-
assay (no=7, mean= 122.6, s.d. = 12.3U -1)
coefficients of variation were 4.9% and 10.0%
respectively. Serum specimens were always frozen at
-20°C immediately after collection, and the
assay was performed within 1 month. Further
determinations were done at 3 and 6 months on 12
samples; a significant decrease in immunoreactivity
was observed (F=3.72, P=0.0405).
Statistical evaluation of the results was performed
by means of the analysis of variance (one way
ANOVA), Bonferroni's test for paired comparisons,
analysis of variance with repeated measures (Brown
et al., 1981), chi-square test, Youden index
(Armitage, 1971).
Figure 1 illustrates serum levels of TPA. A
significantly increased frequency of pathological
values was observed in pancreatic cancer patients
(x2 =68.8, P<0.0005).
Table I reports mean values, standard errors and
statistical evaluation of TPA. Sensitivity, specificity
and diagnostic accuracy (Youden index) in
diagnosing pancreatic cancer were 96.4%, 67.3%
and 63.8% respectively.
Figure 2 shows the individual values of TPA in
pancreatic cancer divided according to the stage of
the disease.
A significant linear correlation was observed in
extrapancreatic diseases between TPA on the one
hand and alanine-amino-transferase and albumin
(increasing and decreasing values) on the other
(r=0.8186, P<0.001 and r=-0.4297, P<0.05
respectively). No significant correlation was
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Figure 1 Individual values of serum TPA. The
continuous line represents the upper normal limit (x
+2s.d. of control subjects: 61.3+44.2U-1). (CS)
control subjects; (PC) pancreatic cancer; (CP) chronic
pancreatitis; (EPD) extra-pancreatic diseases.
Table I Mean values, standard errors and statistical
evaluation of serum TPA
TPA (Ul 1)
Cases
No. x s.e.
Control subjects 29 61.3a 4.1
Pancreatic cancer 28 487.3 90.5
Chronic pancreatitis 24 73.3a 5.6
Extra-pancreatic
diseases 25 131.7a 15.9
106
F= 17.96
P=O.0000
2P<0.001 in respect to pancreatic cancer.
observed between these parameters in pancreatic
cancer and chronic pancreatitis.
In the present study TPA increase was almost
invariably observed in pancreatic cancer patients
(27 out of 28); abnormal values were only
occasionally encountered in chronic pancreatitis (2
out of 24). Both normal and increased serum TPA
levels were found in extra-pancreatic diseases. These
results show that the assay has a good sensitivity
for the detection of pancreatic cancer. The
sensitivity is similar to that previously reported for
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Figure 2 Individual values of TPA in pancreatic
cancer patients divided according to the stage of the
disease. The continuous line represents the upper
normal limit.
Pancreatic oncofoetal antigen (Banwo et al., 1974)
and better than that found for other proposed
tumour markers (Fabris et al., 1981; Farini et al.,
1985; Kalser et al., 1978; Nitti et al., 1982; Reddi &
Holland, 1976; Savarino et al., 1984). The
sensitivity of the test in our hands was better than
that reported by Andriulli et al. (1983) possibly
because our samples were always determined
shortly after collection. In fact a decrease in
immunoreactivity was noted after longer storage.
No clear relationship between the stage of
pancreatic cancer and TPA levels was observed: a
substantial number of patients in T2N1M1 and
T3N1M1 categories had moderately increased serum
TPA. However, the highest values were always
observed in these groups.
TPA levels differentiated pancreatic cancer from
chronic pancreatitis, and to this extent the
specificity of the assay was satisfactory. However,
abnormal TPA values were observed in other than
neoplastic extra-pancreatic diseases. High levels
were frequently found in patients with liver
damage; this is supported by the correlations
observed between alanine-amino-transferase and
albumin on the one hand and TPA on the other.
Such correlations were not found in patients with
chronic pancreatic disease, suggesting that liver
dysfunction does not play an important role in
increasing serum TPA levels in pancreatic cancer.
These data are in full agreement with our
preliminary findings (Panucci et al., 1984), and
confirm the usefulness of TPA in detecting
pancreatic malignancy.
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